
ACC/AHA/ESC PRACTICE GUIDELINES

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society

WRITING COMMITTEE MEMBERS

Douglas P. Zipes, MD, MACC, FAHA, FESC, *Co-Chair*

A. John Camm, MD, FACC, FAHA, FESC, *Co-Chair*

Martin Borggrefe, MD, FESC

Alfred E. Buxton, MD, FACC, FAHA

Bernard Chaitman, MD, FACC, FAHA

Martin Fromer, MD

Gabriel Gregoratos, MD, FACC, FAHA

George Klein, MD, FACC

Arthur J. Moss, MD, FACC, FAHA†

Robert J. Myerburg, MD, FACC, FAHA

Silvia G. Priori, MD, PhD, FESC*

Miguel A. Quinones, MD, FACC

Dan M. Roden, MD, CM, FACC, FAHA

Michael J. Silka, MD, FACC, FAHA

Cynthia Tracy, MD, FACC, FAHA

*European Heart Rhythm Association Official Representative; †Heart Rhythm Society Official Representative

ACC/AHA TASK FORCE MEMBERS

Sidney C. Smith, JR, MD, FACC, FAHA, FESC, *Chair*

Alice K. Jacobs, MD, FACC, FAHA, *Vice-Chair*

Cynthia D. Adams, MSN, APRN-BC, FAHA

Elliott M. Antman, MD, FACC, FAHA‡

Jeffrey L. Anderson, MD, FACC, FAHA

Sharon A. Hunt, MD, FACC, FAHA

Jonathan L. Halperin, MD, FACC, FAHA

Rick Nishimura, MD, FACC, FAHA

Joseph P. Ornato, MD, FACC, FAHA

Richard L. Page, MD, FACC, FAHA

Barbara Riegel, DNSc, RN, FAHA

‡Immediate Past Chair

ESC COMMITTEE FOR PRACTICE GUIDELINES

Silvia G. Priori, MD, PhD, FESC, *Chair*

Jean-Jacques Blanc, MD, FESC, France

Andrzej Budaj, MD, FESC, Poland

A. John Camm, MD, FESC, FACC, FAHA,
United Kingdom

Veronica Dean, France

Jaap W. Deckers, MD, FESC, The Netherlands

Catherine Despres, France

Kenneth Dickstein, MD, PhD, FESC, Norway

John Lekakis, MD, FESC, Greece

Keith McGregor, PhD, France

Marco Metra, MD, Italy

Joao Morais, MD, FESC, Portugal

Ady Osterspey, MD, Germany

Juan Luis Tamargo, MD, FESC, Spain

José Luis Zamorano, MD, FESC, Spain

rhythmias and SCD and the following subtopics: mechanisms, substrates, clinical presentations, ECG, exercise testing, echocardiography, imaging, electrophysiological (EP) testing, drug therapy (antiarrhythmic and nonantiarrhythmic), implantable and external cardioverter devices, ablation, surgery, acute specific arrhythmias (e.g., acute coronary syndrome [ACS], heart failure [HF], stable sustained monomorphic ventricular tachycardia [VT], torsades de pointes), specific pathology (e.g., congenital heart disease, myocarditis, endocrine disorders, renal failure), cardiomyopathies, genetic arrhythmias, structurally normal hearts, athletes, elderly, gender, pediatric, and drug-induced arrhythmias. The complete list of keywords is beyond the scope of this section. The committee reviewed all compiled reports from computerized searches and conducted additional manual searching. Literature citations were generally restricted to published manuscripts appearing in journals in the Index Medicus. Because of the scope and importance of certain ongoing clinical trials and other emerging information, published abstracts were cited in the text when they were the only published information available.

The final recommendations for indications for a diagnostic procedure, a particular therapy, or an intervention for management of patients with ventricular arrhythmias and prevention of SCD summarize both clinical evidence and expert opinion. Once recommendations were written, a Classification of Recommendation and Level of Evidence grade was assigned to each recommendation.

Classification of Recommendations and Level of Evidence are expressed in the ACC/AHA/ESC format as follows:

Classification of Recommendations

- **Class I:** Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.
- **Class II:** Conditions for which there is conflicting evidence and/or divergence of opinion about the usefulness/efficacy of a procedure or treatment.
 - **Class IIa:** Weight of evidence/opinion is in favor of usefulness/efficacy.
 - **Class IIb:** Usefulness/efficacy is less well established by evidence/opinion.
- **Class III:** Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.

Level of Evidence

- **Level of Evidence A:** Data derived from multiple randomized clinical trials or meta-analyses.
- **Level of Evidence B:** Data derived from a single randomized trial or nonrandomized studies.
- **Level of Evidence C:** Only consensus opinion of experts, case studies, or standard-of-care.

The schema for classification of recommendations and level of evidence is summarized in Table 2, which also illustrates how the grading system provides an estimate of the size of treatment effect and an estimate of the certainty of the treatment effect.

Recommendations with respect to therapy have considered the following:

1. The therapy to be offered (implantable cardioverter-defibrillator [ICD], antiarrhythmic drugs, surgery, and miscellaneous other treatments)
2. The point at which therapy is offered (primary prevention for those who are at risk but have not yet had a life-threatening ventricular arrhythmia or sudden cardiac “death” episode, or secondary for those patients who have already experienced such arrhythmias or events)
3. The purpose of therapy (life preservation or symptom reduction/improved quality of life)
4. The etiology of the arrhythmia substrate (coronary heart disease [CHD], cardiomyopathy, or other conditions)
5. The functional status of the patient (New York Heart Association [NYHA] functional class)
6. The state of left ventricular (LV) function (LV ejection fraction [LVEF])
7. The specific arrhythmia concerned (e.g., sustained monomorphic VT, polymorphic VT, and ventricular fibrillation [VF])

Not all therapeutic combinations are clinically relevant, and many have no evidence base and probably will not have one in the future because of the lack of clinical relevance or the relative rarity of the particular grouping. In many instances, the probable value of therapy may be reasonably inferred by the response of similar patients to specific therapies.

1.2. Prophylactic Implantable Cardioverter-Defibrillator Recommendations Across Published Guidelines

The ACC/AHA/NASPE 2002 Guidelines Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices (1), the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (2), the ESC 2001 and 2003 Guidelines on Prevention of Sudden Cardiac Death (3,4), the ESC 2005 Guidelines for the Diagnosis and Treatment of Chronic Heart Failure (5a), and the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (6) include a large number of recommendations on ICD therapy that merit attention.

Recommendations for prophylactic ICD implantation based on ejection fractions (EFs) have been inconsistent because clinical investigators have chosen different EFs for enrollment in trials of therapy, average values of the EF in such trials have been substantially lower than the cutoff value for enrollment, and subgroup analyses of clinical trial populations based on EF have not been consistent in their

New implantable recorders are capable of monitoring the rhythm and can record on patient activation or automatically for prespecified criteria. Although these devices require surgical implantation, they have been shown to be extremely useful in diagnosing serious tachyarrhythmias and bradyarrhythmias in patients with life-threatening symptoms such as syncope (120,146).

5.2.4. Electrocardiographic Techniques and Measurements

Recommendations

Class IIa

It is reasonable to use TWA to improve the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk for developing life-threatening ventricular arrhythmias. (Level of Evidence: A)

Class IIb

ECG techniques such as signal-averaged ECG (SAECG), heart rate variability (HRV), baroflex sensitivity, and heart rate turbulence may be useful to improve the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk of developing life-threatening ventricular arrhythmias. (Level of Evidence: B)

ICD trials, especially Multicenter Automatic Defibrillator Implantation Trial (MADIT) II, have highlighted the need to develop novel tools in order to identify patients at highest risk of ventricular arrhythmias and SCD. Numerous modalities exist at present for assessing this risk but only 2 are currently approved by the U.S. Food and Drug Administration (FDA): SAECG and TWA. However, HRV and baroflex sensitivity also show considerable promise. SAECG improves the signal-to-noise ratio of a surface ECG, permitting the identification of low-amplitude (microvolt level) signals at the end of the QRS complex referred to as “late potentials.” Late potentials indicate regions of abnormal myocardium demonstrating slow conduction, a substrate abnormality that may allow for reentrant ventricular arrhythmias, and they are believed to serve as a marker for the presence of an EP substrate for reentrant ventricular tachyarrhythmias. The presence of an abnormal SAECG was shown to increase the risk of arrhythmic events by 6- to 8-fold in a post-MI setting (147). However, the restoration of patency to the infarct-related coronary artery with fibrinolysis or angioplasty and the widespread use of surgical revascularization have modified the arrhythmogenic substrate, leading to a noticeable reduction in the predictive power of this tool. SAECG in isolation, therefore, is no longer useful for the identification of post-MI patients at risk of ventricular arrhythmias. However, a high negative predictive value of 89% to 99% rendered the SAECG a

useful tool with which to exclude a wide-complex tachycardia as a cause of unexplained syncope (148,149).

TWA, which is a fluctuation in the amplitude or morphology of the T wave that alternates every other beat assessed during exercise testing or atrial pacing, has been shown to be an effective tool for identifying high-risk patients post-MI (150) and in the presence of ischemic or nonischemic cardiomyopathy. This association appears to be independent of EF and equally strong in patients with ischemic and nonischemic cardiomyopathy. TWA appears to have a very high negative predictive accuracy (151–153). TWA may also be used to identify risk of arrhythmic mortality in patients with LV dysfunction due to prior MI (154). In a small study of patients with MADIT II characteristics (post-MI with EF less than or equal to 30%), a microvolt TWA test was found to be better than QRS duration at identifying a high-risk group and also a low-risk group unlikely to benefit from ICD therapy (155).

HRV, which is a beat-to-beat variation in cardiac cycle length resulting from autonomic influence on the sinus node of patients in sinus rhythm, has been shown to independently predict the risk of SCD and total mortality in patients post-MI (156) both with and without impaired LV function (157–159). Observational studies also suggest its usefulness in the presence of nonischemic cardiomyopathy, but this has to be confirmed with large clinical trials. There are many different forms of heart rate analysis, some of which, such as heart rate turbulence, may be more productive than others. Reduced baroflex sensitivity, a quantitative assessment of the ability of the autonomic nervous system to react to acute stimulation involving primarily vagal reflexes, compared with a continuous assessment of basal sympathovagal information provided by HRV, has also proved successful in assessing the risk of SCD both alone (increased inducibility of arrhythmic events including VT during EP testing) (160,161) and when used in combination with HRV (increased risk of cardiac mortality post-MI) (157) and TWA (increased risk of arrhythmic events if both parameters are abnormal in a cohort of patients with ICDs) (162). Additional prospective studies are needed to further clarify the role of these ECG parameters in assessing risk in differing clinical settings.

5.2.5. Left Ventricular Function and Imaging

Recommendations

Class I

1. **Echocardiography is recommended in patients with ventricular arrhythmias who are suspected of having structural heart disease. (Level of Evidence: B)**
2. **Echocardiography is recommended for the subset of patients at high risk for the development of serious ventricular arrhythmias or SCD, such as those with dilated, hypertrophic, or RV cardiomyopathies, AMI survivors, or relatives of patients with inherited disorders associated with SCD. (Level of Evidence: B)**

112. Zipes DP, Wellens HJ. Sudden cardiac death. *Circulation* 1998;98:2334–51.
113. Gardner RA, Kruyer WB, Pickard JS, et al. Nonsustained ventricular tachycardia in 193 U.S. military aviators: long-term follow-up. *Aviat Space Environ Med* 2000;71:783–90.
114. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. *Circulation* 1999;99:518–28.
115. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management, part III. *Circulation* 1999;99:674–81.
116. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 2000;342:1937–45.
117. Rankovic V, Karha J, Passman R, et al. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. *Am J Cardiol* 2002;89:1072–6.
118. Maron BJ. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. *Cardiol Rev* 2002;10:173–81.
119. Zimetbaum P, Josephson ME. Evaluation of patients with palpitations. *N Engl J Med* 1998;338:1369–73.
120. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary. *Eur Heart J* 2004;25:2054–72.
121. Mittal S, Iwai S, Stein KM, et al. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. *J Am Coll Cardiol* 1999;34:1082–9.
122. Farmer DM, Swygman CA, Wang PJ, et al. Evidence that nonsustained polymorphic ventricular tachycardia causes syncope (data from implantable cardioverter defibrillators). *Am J Cardiol* 2003;91:606–9.
123. Steinberg JS, Beckman K, Greene HL, et al. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. *Antiarrhythmics Versus Implantable Defibrillators*. *J Cardiovasc Electrophysiol* 2001;12:996–1001.
124. Andrews NP, Fogel RI, Pelargonio G, et al. Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: a comparison with patients known to have sustained ventricular tachycardia. *J Am Coll Cardiol* 1999;34:2023–30.
125. Link MS, Saeed M, Gupta N, et al. Inducible ventricular flutter and fibrillation predict for arrhythmia occurrence in coronary artery disease patients presenting with syncope of unknown origin. *J Cardiovasc Electrophysiol* 2002;13:1103–8.
126. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. *Am J Cardiol* 2000;85:981–5.
127. Garcia-Moran E, Mont L, Cuesta A, et al. Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator. *Eur Heart J* 2002;23:901–7.
128. Pires LA, May LM, Ravi S, et al. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators. *Am J Cardiol* 2000;85:725–8.
129. LeLorier P, Krahn AD, Klein GJ, et al. Comparison of patients with syncope with left ventricular dysfunction and negative electrophysiologic testing to cardiac arrest survivors and patients with syncope and preserved left ventricular function and impact of an implantable defibrillator. *Am J Cardiol* 2002;90:77–9.
130. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. *Circulation* 1993;88:782–4.
131. Anderson JL, Hallstrom AP, Epstein AE, et al. Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. *The AVID Investigators*. *Circulation* 1999;99:1692–9.
132. Hariman RJ, Hu DY, Gallastegui JL, et al. Long-term follow-up in patients with incessant ventricular tachycardia. *Am J Cardiol* 1990;66:831–6.
133. Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. *J Am Coll Cardiol* 2002;39:1323–8.
134. De Baquer D, De Backer G, Kornitzer M, et al. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women. *J Am Coll Cardiol* 1998;32:680–5.
135. Kors JA, de Bruyne MC, Hoes AW, et al. T-loop morphology as a marker of cardiac events in the elderly. *J Electrocardiol* 1998;31 Suppl:54–9.
136. Kors JA, de Bruyne MC, Hoes AW, et al. T axis as an indicator of risk of cardiac events in elderly people. *Lancet* 1998;352:601–5.
137. Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. *Circulation* 1991;84:1516–23.
138. Algra A, Tijssen JG, Roelandt Jr., et al. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. *Br Heart J* 1993;70:43–8.
139. Maury P, Couderc P, Delay M, et al. Electrical storm in Brugada syndrome successfully treated using isoprenaline. *Europace* 2004;6:130–3.
140. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? *Cardiology* 2000;94:99–102.
141. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol* 2002;40:1531–40.
142. Podrid PJ, Graboys TB. Exercise stress testing in the management of cardiac rhythm disorders. *Med Clin North Am* 1984;68:1139–52.
143. Califf RM, McKinnis RA, McNeer JF, et al. Prognostic value of ventricular arrhythmias associated with treadmill exercise testing in patients studied with cardiac catheterization for suspected ischemic heart disease. *J Am Coll Cardiol* 1983;2:1060–7.
144. Young DZ, Lampert S, Graboys TB, et al. Safety of maximal exercise testing in patients at high risk for ventricular arrhythmia. *Circulation* 1984;70:184–91.
145. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. *Am J Cardiol* 1990;66:214–9.
146. Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. *Reveal Investigators*. *Circulation* 1999;99:406–10.
147. Steinberg JS, Berbari EJ. The signal-averaged electrocardiogram: update on clinical applications. *J Cardiovasc Electrophysiol* 1996;7:972–88.
148. Cook Jr., Flack JE, Gregory CA, et al. Influence of the preoperative signal-averaged electrocardiogram on left ventricular function after coronary artery bypass graft surgery in patients with left ventricular dysfunction. *The CABG Patch Trial*. *Am J Cardiol* 1998;82:285–9.
149. Steinberg JS, Prystowsky E, Freedman RA, et al. Use of the signal-averaged electrocardiogram for predicting inducible ventricular tachycardia in patients with unexplained syncope: relation to clinical variables in a multivariate analysis. *J Am Coll Cardiol* 1994;23:99–106.
150. Ikeda T, Saito H, Tanno K, et al. T-wave alternans as a predictor for sudden cardiac death after myocardial infarction. *Am J Cardiol* 2002;89:79–82.
151. Hohnloser SH, Klingenhoben T, Bloomfield D, et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. *J Am Coll Cardiol* 2003;41:2220–4.
152. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med* 2004;351:2481–8.
153. Bloomfield DM, Bigger JT, Steinman RC, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. *J Am Coll Cardiol* 2006;47:456–63.
154. Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. *J Am Coll Cardiol* 2006;47:1820–7.

155. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. *Circulation* 2004;110:1885–9.
156. Zuanetti G, Neilson JM, Latini R, et al. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. *Circulation* 1996;94:432–6.
157. La Rovere MT, Bigger JT Jr., Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998;351:478–84.
158. Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). *J Am Coll Cardiol* 2000;35:1263–75.
159. Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. *Circulation* 2004;109:990–6.
160. Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. *Circulation* 1991;83:945–52.
161. Farrell TG, Odemuyiwa O, Bashir Y, et al. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. *Br Heart J* 1992;67:129–37.
162. Hohnloser SH, Klingenhoben T, Li YG, et al. T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers. *J Cardiovasc Electrophysiol* 1998;9:1258–68.
163. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. *Circulation* 1997;95:1686–744.
164. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Coll Cardiol* 2003;42:954–70.
165. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr* 1989;2:358–67.
166. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol* 2002;90:29–34.
167. Chuang ML, Hibberd MG, Salton CJ, et al. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. *J Am Coll Cardiol* 2000;35:477–84.
168. Foster RE, Johnson DB, Barilla F, et al. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction. *Am Heart J* 1998;136:269–75.
169. Kies P, Bootsma M, Bax J, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. *Heart Rhythm* 2006;3:225–34.
170. Marcus F, Towbin JA, Zareba W, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design and protocol. *Circulation* 2003;107:2975–8.
171. Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. *J Am Coll Cardiol* 2004;44:1164–71.
172. Diethelm L, Simonson JS, Dery R, et al. Determination of left ventricular mass with ultrafast CT and two-dimensional echocardiography. *Radiology* 1989;171:213–7.
173. Yamaoka O, Fujioka H, Haque T, et al. Low-dose dobutamine stress test for the evaluation of cardiac function using ultrafast computed tomography. *Clin Cardiol* 1993;16:473–9.
174. Thomson HL, Basmadjian AJ, Rainbird AJ, et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. *J Am Coll Cardiol* 2001;38:867–75.
175. Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. *Circulation* 1995;92:2157–62.
176. He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. *Circulation* 2000;101:244–51.
177. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). *J Am Coll Cardiol* 2003;42:1318–33.
178. Wellens HJ, Schuilenburg RM, Durrer D. Electrical stimulation of the heart in patients with ventricular tachycardia. *Circulation* 1972;46:216–26.
179. Ross DL, Farre J, Bar FW, et al. Comprehensive clinical electrophysiologic studies in the investigation of documented or suspected tachycardias. Time, staff, problems and costs. *Circulation* 1980;61:1010–6.
180. Freedman RA, Swerdlow CD, Soderholm-Difatte V, et al. Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. *Am J Cardiol* 1988;61:578–82.
181. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. *N Engl J Med* 1988;318:19–24.
182. Kuchar DL, Rottman J, Berger E, et al. Prediction of successful suppression of sustained ventricular tachyarrhythmias by serial drug testing from data derived at the initial electrophysiologic study. *J Am Coll Cardiol* 1988;12:982–8.
183. Fromer M, Shenasa M. A critical reappraisal of serial electrophysiologic drug testing for sustained ventricular tachycardia. *Am Heart J* 1987;114:1537–41.
184. Bachinsky WB, Linzer M, Weld L, et al. Usefulness of clinical characteristics in predicting the outcome of electrophysiologic studies in unexplained syncope. *Am J Cardiol* 1992;69:1044–9.
185. Swerdlow CD, Bardy GH, McNulty J, et al. Determinants of induced sustained arrhythmias in survivors of out-of-hospital ventricular fibrillation. *Circulation* 1987;76:1053–60.
186. Spielman SR, Greenspan AM, Kay HR, et al. Electrophysiologic testing in patients at high risk for sudden cardiac death. I. Nonsustained ventricular tachycardia and abnormal ventricular function. *J Am Coll Cardiol* 1985;6:31–40.
187. Baerman JM, Morady F, de Buitelir M, et al. A prospective comparison of programmed ventricular stimulation with triple extrastimuli versus single and double extrastimuli during infusion of isoproterenol. *Am Heart J* 1989;117:342–7.
188. Summitt J, Rosenheck S, Kou WH, et al. Effect of basic drive cycle length on the yield of ventricular tachycardia during programmed ventricular stimulation. *Am J Cardiol* 1990;65:49–52.
189. Morady F, DiCarlo L, Winston S, et al. A prospective comparison of triple extrastimuli and left ventricular stimulation in studies of ventricular tachycardia induction. *Circulation* 1984;70:52–7.
190. Morady F, Kadish A, Rosenheck S, et al. Concealed entrainment as a guide for catheter ablation of ventricular tachycardia in patients with prior myocardial infarction. *J Am Coll Cardiol* 1991;17:678–89.